Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study.

BMC cancer - 19 Nov 2021

Miyawaki Taichi, Kenmotsu Hirotsugu, Kodama Hiroaki, Nishioka Naoya, Miyawaki Eriko, Mamesaya Nobuaki, Kobayashi Haruki, Omori Shota, Ko Ryo, Wakuda Kazushige, Ono Akira, Naito Tateaki, Murakami Haruyasu, Mori Keita, Harada Hideyuki, Endo Masahiro, Takahashi Kazuhisa, Takahashi Toshiaki

Abstract excerpt

BACKGROUND: Local ablative therapy (LAT) may be beneficial for patients with epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC) with oligo-residual disease after treatment with EGFR tyrosine kinase inhibitor (EGFR-TKI). However, this has not been fully established. This study aimed to evaluate the predominant progressive disease (PD) pattern limited to residual sites of disease...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Afatinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aniline Compounds

Share to Erlotinib Hydrochloride

Share to Gefitinib

Share to Genes, erbB-1

Share to Neoplasm, Residual

Share to Treatment Failure

Source

Open in PubMed Open full text

Identifiers

PMID: 34798865
DOI: 10.1186/s12885-021-08983-2
PMCID: PMC8605535

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study.PMID 34798865Read ↗

Current Status of Multimodal Therapy for Oligometastatic Disease, Induced Oligometastatic Disease and Oligo-Progressive Disease in EGFR-Mutated Non-Small Cell Lung CancerSemantic proximity Read ↗

ATOM: A phase II study to assess efficacy of preemptive local ablative therapy to residual oligometastases of NSCLC after EGFR TKI.Semantic proximity Read ↗

Oligoprogression in NSCLC with Other Actionable Oncogenic Drivers Beyond EGFR and ALK: An Emerging Entity.Semantic proximity Read ↗

Management of Oligometastasis and Oligoprogression in Patients with Epidermal Growth Factor Receptor Mutation-Positive NSCLC in the Era of Third-Generation Tyrosine Kinase Inhibitors.Semantic proximity Read ↗

Oligoprogressive Non-Small-Cell Lung Cancer under Treatment with PD-(L)1 InhibitorsSemantic proximity Read ↗

Examination of the effectiveness of local therapy for oligo-recurrence of EGFR-mutated NSCLC.Semantic proximity Read ↗

Pattern of failure and clinical value of local therapy for oligo-recurrence in locally advanced non-small cell lung cancer after definitive chemoradiation: Impact of driver mutation status.Semantic proximity Read ↗

Local Therapy for Oligoprogressive Disease in Patients With Advanced Stage Non-small-cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation.Semantic proximity Read ↗

RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation.Semantic proximity Read ↗

Consolidative Local Ablative Therapy Improves the Survival of Patients With Synchronous Oligometastatic NSCLC Harboring EGFR Activating Mutation Treated With First-Line EGFR-TKIs.Semantic proximity Read ↗

Pattern of Recurrence Analysis in Metastatic EGFR-Mutant NSCLC Treated with Osimertinib: Implications for Consolidative Stereotactic Body Radiation Therapy.Semantic proximity Read ↗

The local therapy strategy in progressive ALK or EGFR non-small cell lung cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.